Fig. 4.

Therapies received among patients who received EGFR-TKI in second or later line and were tested for EGFR T790M.

2 L+: second or later line; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor.

^a Patients still treated with their first EGFR-TKI therapy in the month prior to data cutoff were considered as remaining on EGFR-TKI therapy.

^b Targeted therapies included EGFR-TKIs, monoclonal antibody inhibitors, ALK inhibitors, and angiogenesis inhibitors.

^c The proportion of patients who received afatinib, erlotinib and osimertinib are calculated over the total number of patients in the subgroup (e.g. the 109 patients for the analysis of patients not tested for EGFR T790M).